140 related articles for article (PubMed ID: 18183078)
1. The efficacy of neoadjuvant androgen deprivation therapy as a prostate volume reduction before brachytherapy for clinically localized prostate cancer.
Ebara S; Manabe D; Kobayashi Y; Tanimoto R; Saika T; Nasu Y; Saito S; Satoh T; Miki K; Hashine K; Kumon H
Acta Med Okayama; 2007 Dec; 61(6):335-40. PubMed ID: 18183078
[TBL] [Abstract][Full Text] [Related]
2. Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy.
Kucway R; Vicini F; Huang R; Stromberg J; Gonzalez J; Martinez A
J Urol; 2002 Jun; 167(6):2443-7. PubMed ID: 11992054
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of neoadjuvant bicalutamide and dutasteride as a cytoreductive regimen before prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen ZA; Kurko B
Urology; 2006 Jul; 68(1):116-20. PubMed ID: 16844453
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Immediate Switching from Bicalutamide to Flutamide as Second-Line Combined Androgen Blockade.
Yokomizo Y; Kawahara T; Miyoshi Y; Otani M; Yamanaka S; Teranishi J; Noguchi K; Yao M; Uemura H
Biomed Res Int; 2016; 2016():4083183. PubMed ID: 27493956
[TBL] [Abstract][Full Text] [Related]
5. The effect of brachytherapy, external beam irradiation and hormonal therapy on prostate volume.
Stone NN; Stock RG
J Urol; 2007 Mar; 177(3):925-8. PubMed ID: 17296377
[TBL] [Abstract][Full Text] [Related]
6. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza Rodríguez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; Villà S; Perez de la Haza A; Calvo FA
Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876
[TBL] [Abstract][Full Text] [Related]
7. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
Soga N; Hori Y; Ogura Y; Hayashi N; Sugimura Y
Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406
[TBL] [Abstract][Full Text] [Related]
8. Chemical castration and anti-androgens induce differential gene expression in prostate cancer.
Lehmusvaara S; Erkkilä T; Urbanucci A; Waltering K; Seppälä J; Larjo A; Tuominen VJ; Isola J; Kujala P; Lähdesmäki H; Kaipia A; Tammela TLj; Visakorpi T
J Pathol; 2012 Jul; 227(3):336-45. PubMed ID: 22431170
[TBL] [Abstract][Full Text] [Related]
9. Radiotherapy Plus GnRH Analogue
Buwenge M; Deodato F; Macchia G; Siepe G; Zhao X; Valicenti RK; Cilla S; Alitto AR; Ntreta M; Bisello S; Mantini G; Valentini V; Morganti AG; Cammelli S
Anticancer Res; 2019 Nov; 39(11):6373-6378. PubMed ID: 31704870
[TBL] [Abstract][Full Text] [Related]
10. Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer.
Morote J; Esquena S; Abascal JM; Trilla E; Cecchini L; Raventós CX; Catalán R; Reventós J
Urol Int; 2006; 77(2):135-8. PubMed ID: 16888418
[TBL] [Abstract][Full Text] [Related]
11. [Usefulness and positioning of MAB therapy for prostate cancer].
Akaza H; Chodak GW; Hirao Y
Gan To Kagaku Ryoho; 2005 Oct; 32(10):1507-20. PubMed ID: 16227758
[TBL] [Abstract][Full Text] [Related]
12. Impact of a novel neoadjuvant and adjuvant hormone-deprivation approach on quality of life, voiding function, and sexual function after prostate brachytherapy.
Miller NL; Bissonette EA; Bahnson R; Wilson J; Theodorescu D
Cancer; 2003 Mar; 97(5):1203-10. PubMed ID: 12599226
[TBL] [Abstract][Full Text] [Related]
13. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
Soga N; Arima K; Sugimura Y
Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
[TBL] [Abstract][Full Text] [Related]
14. [Hormonal therapy for prostate cancer: methods and prognosis].
Huang BX; Su HC; Cao WL; Sun FK
Zhonghua Nan Ke Xue; 2013 Sep; 19(9):815-9. PubMed ID: 24386861
[TBL] [Abstract][Full Text] [Related]
15. Commentary on "Intermittent versus continuous androgen deprivation in prostate cancer." Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM Jr, University of Michigan, Division of Hematology/Oncology, Ann Arbor, MI. N Engl J Med 2013; 368(14):1314-25. doi: 10.1056/NEJMoa1212299.
Eggener S
Urol Oncol; 2014 Aug; 32(6):936-7. PubMed ID: 25087673
[TBL] [Abstract][Full Text] [Related]
16. Commentary on "Intermittent versus continuous androgen deprivation in prostate cancer." Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM Jr., University of Michigan, Division of Hematology/Oncology, 1500 E Medical Center Dr., 7314 CC, Ann Arbor, MI. N Engl J Med 2013;368(14):1314-25.
Trump DL
Urol Oncol; 2013 Nov; 31(8):1847. PubMed ID: 24210086
[TBL] [Abstract][Full Text] [Related]
17. [Prostate cancer - androgen deprivation: intermittent or continuous?].
Wedel SA
Aktuelle Urol; 2014 May; 45(3):180-1. PubMed ID: 24932555
[No Abstract] [Full Text] [Related]
18. Re: Intermittent versus continuous androgen deprivation in prostate cancer.
Taneja SS
J Urol; 2013 Dec; 190(6):2093-4. PubMed ID: 24209518
[No Abstract] [Full Text] [Related]
19. The effect of concurrent androgen deprivation and 3D conformal radiotherapy on prostate volume and clinical organ doses during treatment for prostate cancer.
Onal C; Topkan E; Efe E; Yavuz M; Arslan G; Yavuz A
Br J Radiol; 2009 Dec; 82(984):1019-26. PubMed ID: 19581310
[TBL] [Abstract][Full Text] [Related]
20. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy.
Hinerman-Mulroy A; Merrick GS; Butler WM; Wallner KE; Allen Z; Adamovich E
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1367-82. PubMed ID: 15275722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
